Using Azacitidine to Prevent Kidney Damage After Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of azacitidine, a demethylating agent, to prevent the progression from acute kidney injury (AKI) to chronic kidney disease (CKD) in patients who have undergone cardiac surgery. The study focuses on understanding the role of pericytes, which are cells involved in kidney scarring, and how their epigenetic modifications contribute to kidney damage. By administering azacitidine, the researchers aim to reverse these modifications and reduce fibrogenesis, potentially improving kidney outcomes for affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with cardiac surgery associated-AKI, stage 2 and stage 3

Exclusion Criteria:

* Chronic kidney disease
* Decompensated heart failure (EF \< 45%)
* Liver cirrhosis, child B or C
* Acute infection
* Acute bleeding
* Long-term use of immunosuppressant other than azacitidine
* Patients with active cancer other than acute leukemia or myelodysplastic syndrome
* Leukopenia, anemia or thrombocytopenia
* Pregnancy

Where it's running

• Yu Hsiang Chou
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Yu Hsiang Chou, PhD — National Taiwan University Hospital
• Study coordinator: Yu Hsiang Chou, PhD
• Email: chouyuhsiang11@gmail.com
• Phone: 886-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AST-120 (Kremezin) for kidney protection and slowing decline after acute kidney disease

  This study will test whether adding AST-120 (Kremezin) to standard care lowers protein-bound uremic toxins and helps slow kidney decline in adults recovering from acute kidney disease.

  Recruiting Phase 4 Chang Gung Memorial Hospital · Taoyuan · NCT07182422

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.